Increased serum levels of adhesion molecules ICAM-1 and VCAM-1 in systemic sclerosis are not specific for pulmonary manifestations.

Authors:
Vivek Thakkar
Vivek Thakkar
St Vincent's Hospital Melbourne
Australia
Karen A Patterson
Karen A Patterson
Flinders University
Bedford Park | Australia
Wendy Stevens
Wendy Stevens
University of the Witwatersrand
South Africa
Michelle Wilson
Michelle Wilson
Auckland City Hospital
Auckland | New Zealand
Janet Roddy
Janet Roddy
St Vincent's Hospital Melbourne
Australia
Joanne Sahhar
Joanne Sahhar
The University of Melbourne
Australia
Susanna Proudman
Susanna Proudman
Royal Adelaide Hospital
Adelaide | Australia
Pravin Hissaria
Pravin Hissaria
Royal Adelaide Hospital
Australia

Clin Rheumatol 2018 Jun 23;37(6):1563-1571. Epub 2018 Apr 23.

Department of Rheumatology, St Vincent's Hospital (Melbourne), 41 Parade, Fitzroy, VIC, 3065, Australia.

Studies suggest elevated serum intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) levels may be markers of pulmonary arterial hypertension in systemic sclerosis (SSc-PAH). We sought to evaluate whether ICAM-1 and VCAM-1 levels are useful screening biomarkers for incident SSc-PAH. In this cross-sectional study, four groups were selected from the Australian Scleroderma Cohort Study: group 1 (n = 15) had definite PAH; group 2 (n = 19) had interstitial lung disease (ILD); group 3 (n = 30) were SSc-controls; and group 4 (n = 34) were healthy controls. Serum ICAM-1 and VCAM-1 levels were measured using the Millipore Milliplex MAP Human 2-Plex Panel. There were no differences in ICAM-1 levels in the PAH versus ILD group (263.0 ± 85.4 vs 380.4 ± 168.3 ng/mL, p = 0.136), SSc-controls (263.0 ± 85.4 vs 253.1 ± 98.0 ng/mL, p = 1.00), or healthy controls (263.0 ± 85.4 vs 201.8 ± 57.2 ng/mL, p = 0.093). Similarly, there were no differences in VCAM-1 level in PAH versus ILD groups (1476.2 ± 434.9 vs 1424.8 ± 527.6 ng/mL, p = 1.00) and SSc-controls (1476.2 ± 434.9 vs 1409.5 ± 341.1 ng/mL, p = 1.00). SSc subjects had significantly higher levels of ICAM-1 (297.4 ± 134.0 vs 201.8 ± 57.2 ng/mL, p < 0.0001) and VCAM-1 compared to healthy controls (1432.7 ± 427.4 vs 1125.6 ± 273.4 ng/mL, p < 0.0001). Neither ICAM-1 nor VCAM-1 is a specific screening biomarker of SSc-PAH. Instead, increased levels of these adhesion molecules in SSc, irrespective of pulmonary complications, suggest that they may play a role in SSc pathogenesis.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-018-4081-7DOI Listing

Still can't find the full text of the article?

Sign up to send a request to the authors directly.
June 2018
4 Reads

Publication Analysis

Top Keywords

vcam-1 levels
12
icam-1 vcam-1
12
pah versus
8
systemic sclerosis
8
healthy controls
8
ild group
8
versus ild
8
adhesion molecule-1
8
icam-1
6
levels
6
vcam-1
5
group
5
vcam-1 level
4
n = 19 interstitial
4
group n = 19
4
ild groups
4
level pah
4
disease ild
4
differences vcam-1
4
group n = 30
4

Similar Publications